Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 8-K

BIOPHAN TECHNOLOGIES INC Form 8-K July 19, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 13, 2004

BIOPHAN TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

150 LUCIUS GORDON DRIVE, SUITE 215

WEST HENRIETTA, NEW YORK

(Address of principal executive offices)

(Zip code)

(585) 214-2441
-----(Registrant's telephone number)

-2-

Item 9. Regulation FD Disclosure

On July 13, 2004, the Company held its Annual Stockholders Meeting and, in addition to the conduct of regular business matters, announced that John Lanzafame, former President of STS Polymers, which was acquired earlier this year by Angiotech Pharmaceuticals (NasdaqNM:ANPI), is leading Biophan's efforts related to the use of the Company's nanomagnetic particle coating technology for drug delivery applications, including controlled drug release using electromagnetic fields. A Powerpoint presentation provided by Mr. Lanzafame was presented at the Meeting, and is available for viewing on the Company's website at www.biophan.com/2004.php. The Company also announced that Nanoset, LLC, its nanomagnetic particle technology partner, had filed several patents on the technology, including a 540 page patent application filed two weeks prior to the meeting. Biophan holds the worldwide exclusive license for medical applications developed by Nanoset.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 8-K

-3-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOPHAN TECHNOLOGIES, INC.
-----(Registrant)

Date: July 19, 2004 /s/ Robert J. Wood (Signature)

Robert J. Wood CFO, Treasurer (Principal Financial Officer)